These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35281934)

  • 1. Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis.
    Qin D; Tao QF; Huang SL; Chen M; Zheng H
    Front Pharmacol; 2022; 13():757969. PubMed ID: 35281934
    [No Abstract]   [Full Text] [Related]  

  • 2. Acupuncture vs. antispasmodics in the treatment of irritable bowel syndrome: An adjusted indirect treatment comparison meta-analysis.
    Shi YZ; Tao QF; Qin D; Chen M; Yu SG; Zheng H
    Front Physiol; 2022; 13():1001978. PubMed ID: 36277191
    [No Abstract]   [Full Text] [Related]  

  • 3. Chinese herbal medicine versus antispasmodics in the treatment of irritable bowel syndrome: A network meta-analysis.
    Chen M; Qin D; Huang SL; Tang TC; Zheng H
    Neurogastroenterol Motil; 2021 Aug; 33(8):e14107. PubMed ID: 33660903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.
    Ruepert L; Quartero AO; de Wit NJ; van der Heijden GJ; Rubin G; Muris JW
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD003460. PubMed ID: 21833945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.
    Brenner DM; Dove LS; Andrae DA; Covington PS; Gutman C; Chey WD
    Neurogastroenterol Motil; 2018 Mar; ():e13331. PubMed ID: 29575372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of antispasmodic agents, alone or in combination, in the treatment of Irritable Bowel Syndrome: systematic review and meta-analysis.
    Martínez-Vázquez MA; Vázquez-Elizondo G; González-González JA; Gutiérrez-Udave R; Maldonado-Garza HJ; Bosques-Padilla FJ
    Rev Gastroenterol Mex; 2012; 77(2):82-90. PubMed ID: 22672854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis.
    Black CJ; Burr NE; Camilleri M; Earnest DL; Quigley EM; Moayyedi P; Houghton LA; Ford AC
    Gut; 2020 Jan; 69(1):74-82. PubMed ID: 30996042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome.
    Quartero AO; Meineche-Schmidt V; Muris J; Rubin G; de Wit N
    Cochrane Database Syst Rev; 2005 Apr; (2):CD003460. PubMed ID: 15846668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis.
    Black CJ; Yuan Y; Selinger CP; Camilleri M; Quigley EMM; Moayyedi P; Ford AC
    Lancet Gastroenterol Hepatol; 2020 Feb; 5(2):117-131. PubMed ID: 31859183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
    Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
    Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biofeedback for treatment of irritable bowel syndrome.
    Goldenberg JZ; Brignall M; Hamilton M; Beardsley J; Batson RD; Hawrelak J; Lichtenstein B; Johnston BC
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31713856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea.
    Fragkos KC
    Clin Exp Gastroenterol; 2017; 10():229-240. PubMed ID: 28989282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pinaverium bromide in the treatment of irritable bowel syndrome: a systematic review and meta-analysis.
    Bor S; Lehert P; Chalbaud A; Tack J
    Therap Adv Gastroenterol; 2021; 14():17562848211033740. PubMed ID: 34539813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q; Zhang Y; Chen F; Zuo X; Li Y
    BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of antispasmodics in the treatment of irritable bowel syndrome.
    Annaházi A; Róka R; Rosztóczy A; Wittmann T
    World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
    Cash BD; Lacy BE; Rao T; Earnest DL
    Expert Opin Pharmacother; 2016; 17(3):311-22. PubMed ID: 26559529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.